Sangamo Therapeutics Inc. (SGMO) and Pfizer Inc. (PFE) on Wednesday said they will collaborate to develop a potential gene therapy to treat certain neurodegenerative disorders caused by a gene mutation.
The therapy would use zinc finger protein transcription factors, or ZFP-TFs, to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the C9ORF72 gene, which is linked to approximately one-third of cases of familial ALS. There are no cures currently to halt or reverse the progression of ALS or FTLD.
Under the agreement, Sangamo will receive a $12 million upfront payment from Pfizer and be responsible for developing ZFP-TF candidates, the companies said. Sangamo also is eligible to receive up to $150 million in milestone payments, as well as tiered royalties on net sales.
Pfizer is responsible for development of the C9ORF72 ZFP-TF program and any resulting products.
Sangamo shares rose 3.4% in premarket trading Wednesday.
Write to Sarah Coffey at firstname.lastname@example.org
(END) Dow Jones Newswires
January 03, 2018 08:09 ET (13:09 GMT)